Acute leukemias in children with Down syndrome

Area of Science:

• Hematology
• Genetics
• Pediatric Oncology

Background:

• Children with Down syndrome (DS) exhibit frequent hematopoietic abnormalities.
• DS patients face a significantly elevated risk for developing leukemia compared to the general pediatric population.
• Specific risks include transient myeloproliferative disease (3-10% of newborns with DS) and higher incidences of AMKL and ALL.

Purpose of the Study:

• To review the distinct characteristics of leukemias in children with Down syndrome.
• To examine the pathogenesis of these leukemias within the context of trisomy 21.
• To identify future research directions and potential therapeutic strategies.

Main Methods:

• Literature review focusing on Down syndrome and leukemia.
• Analysis of genetic factors related to trisomy 21 and leukemogenesis.
• Synthesis of current knowledge on leukemia subtypes (AMKL, ALL) in DS.

Main Results:

• Children with DS are 500 times more likely to develop AMKL and 20 times more likely to develop ALL.
• Leukemia development in DS is influenced by the unique genetic background of trisomy 21.
• Transient myeloproliferative disease is a common finding in newborns with DS.

Conclusions:

• Understanding the unique genetic landscape of trisomy 21 is crucial for comprehending leukemia development in Down syndrome.
• Further research is needed to elucidate specific molecular mechanisms driving leukemogenesis in DS.
• Targeted therapeutic approaches for leukemia in Down syndrome patients hold promise for improved outcomes.